Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SAR444200
i
Other names:
SAR444200
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sanofi
Drug class:
TCR modulator, GPC-3 inhibitor
Related drugs:
‹
afamitresgene autoleucel (3)
TAEST16001 (2)
ADP-A2M10 (1)
AFNT-211 (1)
BSB-1001 (1)
IMC-C103C (1)
GSK3377794 (1)
TBI-1301 (1)
ADP-A2AFP (0)
E6 TCR (0)
E7 TCR-T (0)
FH-TCR-Tᴍsʟɴ (0)
HA-1 T TCR T Cell Immunotherapy (0)
HRYZ-T101 (0)
IMA101 (0)
IMA201 (0)
IMA203CD8 (0)
IMA401 (0)
IMA402 (0)
KIND T (0)
KITE-718 (0)
LYL132 (0)
LYL331 (0)
LioCyx-M (0)
MAGE A3 TCR (0)
MCC1 TCR (0)
N201 (0)
NT-175 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
NeoTCR-P1 (0)
SCG101 (0)
T-Plex-200-A0201/204-A0201 (0)
T-cell receptor therapy (0)
TBI 1201 (0)
TSC-100 (0)
TSC-101 (0)
TSC-200-A0201 (0)
TSC-204-A0201 (0)
TSC-204-C0702 (0)
YK0901 (0)
mono TRuC-T CD70 cell therapy (0)
multiplexed MAGEA1/PRAME TCR-T cell therapy (0)
RG7686 (1)
BOS-342 (0)
CM350 (0)
ECT204 (0)
ERY974 (0)
NILK-2501 (0)
NILK-3801 (0)
NY-303 (0)
SENTI-301A (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
iCAR-ILC-N101 (0)
afamitresgene autoleucel (3)
TAEST16001 (2)
ADP-A2M10 (1)
AFNT-211 (1)
BSB-1001 (1)
IMC-C103C (1)
GSK3377794 (1)
TBI-1301 (1)
ADP-A2AFP (0)
E6 TCR (0)
E7 TCR-T (0)
FH-TCR-Tᴍsʟɴ (0)
HA-1 T TCR T Cell Immunotherapy (0)
HRYZ-T101 (0)
IMA101 (0)
IMA201 (0)
IMA203CD8 (0)
IMA401 (0)
IMA402 (0)
KIND T (0)
KITE-718 (0)
LYL132 (0)
LYL331 (0)
LioCyx-M (0)
MAGE A3 TCR (0)
MCC1 TCR (0)
N201 (0)
NT-175 (0)
NY-ESO-1 TCR (0)
NY-ESO-1 TCR-T cell therapy (0)
NeoTCR-P1 (0)
SCG101 (0)
T-Plex-200-A0201/204-A0201 (0)
T-cell receptor therapy (0)
TBI 1201 (0)
TSC-100 (0)
TSC-101 (0)
TSC-200-A0201 (0)
TSC-204-A0201 (0)
TSC-204-C0702 (0)
YK0901 (0)
mono TRuC-T CD70 cell therapy (0)
multiplexed MAGEA1/PRAME TCR-T cell therapy (0)
RG7686 (1)
BOS-342 (0)
CM350 (0)
ECT204 (0)
ERY974 (0)
NILK-2501 (0)
NILK-3801 (0)
NY-303 (0)
SENTI-301A (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
iCAR-ILC-N101 (0)
›
Associations
News
Trials
Filter by
Latest
12ms
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2030 --> Dec 2030 | Trial primary completion date: May 2030 --> Dec 2030
12 months ago
Trial completion date • Trial primary completion date • Metastases
|
ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Tecentriq (atezolizumab) • SAR444200
over1year
Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results (ESMO 2023)
Conclusions These preliminary results from the first two DLs suggest that SAR444200 is tolerable at the tested DLs in patients with advanced solid tumors. Dose escalation continues at this time.
over 1 year ago
Clinical • P1/2 data • Metastases
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
SAR444200
over1year
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: May 2029 --> May 2030 | Trial primary completion date: May 2029 --> May 2030
over 1 year ago
Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Trial completion date: Feb 2028 --> May 2029 | Trial primary completion date: Feb 2028 --> May 2029
2 years ago
Trial completion date • Trial primary completion date
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
over2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Recruiting, Sanofi | Not yet recruiting --> Recruiting
over 2 years ago
Enrollment open
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
over2years
Dose Escalation and Expansion Study of SAR444200 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=106, Not yet recruiting, Sanofi
over 2 years ago
New P1/2 trial
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
Libtayo (cemiplimab-rwlc) • SAR444200
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login